Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction

Chen, Zhi; Chen, Long; Zeng, Chunyu; Wang, Wei Eric

doi:10.1155/2018/7045245

Cited by 51 publications

(50 citation statements)

References 149 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, the possibility of independent modulation of material properties of the building blocks, including stiffness and adhesive ligand composition, can be performed with different cell types, allowing tuning of conditions appropriate for many different populations of therapeutic cells for specific downstream applications in vivo (e.g., delivery to heart, bone, skin, nerves, etc.). MSCs represent a promising therapeutic cell population for tissue/organ regeneration, with local therapy showing some positive effects in human disease . Deployment of a high concentration of MSCs within a regenerative scaffold material immediately before delivery to tissue may improve their efficacy and overcome a manufacturing hurdle of other scaffold materials that require stem cells to be incorporated during scaffold synthesis.…”

mentioning

confidence: 99%

Enhanced In Vivo Delivery of Stem Cells using Microporous Annealed Particle Scaffolds

Koh

Griffin

Archang

et al. 2019

Small

View full text Add to dashboard Cite

Delivery to the proper tissue compartment is a major obstacle hampering the potential of cellular therapeutics for medical conditions. Delivery of cells within biomaterials may improve localization, but traditional and newer void‐forming hydrogels must be made in advance with cells being added into the scaffold during the manufacturing process. Injectable, in situ cross‐linking microporous scaffolds are recently developed that demonstrate a remarkable ability to provide a matrix for cellular proliferation and growth in vitro in three dimensions. The ability of these scaffolds to deliver cells in vivo is currently unknown. Herein, it is shown that mesenchymal stem cells (MSCs) can be co‐injected locally with microparticle scaffolds assembled in situ immediately following injection. MSC delivery within a microporous scaffold enhances MSC retention subcutaneously when compared to cell delivery alone or delivery within traditional in situ cross‐linked nanoporous hydrogels. After two weeks, endothelial cells forming blood vessels are recruited to the scaffold and cells retaining the MSC marker CD29 remain viable within the scaffold. These findings highlight the utility of this approach in achieving localized delivery of stem cells through an injectable porous matrix while limiting obstacles of introducing cells within the scaffold manufacturing process.

show abstract

mentioning

confidence: 99%

Enhanced In Vivo Delivery of Stem Cells using Microporous Annealed Particle Scaffolds

Koh

Griffin

Archang

et al. 2019

Small

View full text Add to dashboard Cite

show abstract

“…The in vitro preconditioning of stem cells aims to prepare the cells for the ischemic environment prior to transplantation and is among the possible solutions that have demonstrated significant enhancement in infarction site recovery [ 34 , 35 ]. The cells can be preconditioned via various methods, including but not limited to pretreatment with hypoxia, drugs, biological agents, and growth factors ( Figure 1 ) [ 31 , 36 , 37 ].…”

Section: Stem Cell Preconditioning For MI Treatmentmentioning

confidence: 99%

Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment

Raziyeva

Smagulova

Kim

et al. 2020

IJMS

View full text Add to dashboard Cite

Ischemic heart disease and myocardial infarction remain leading causes of mortality worldwide. Existing myocardial infarction treatments are incapable of fully repairing and regenerating the infarcted myocardium. Stem cell transplantation therapy has demonstrated promising results in improving heart function following myocardial infarction. However, poor cell survival and low engraftment at the harsh and hostile environment at the site of infarction limit the regeneration potential of stem cells. Preconditioning with various physical and chemical factors, as well as genetic modification and cellular reprogramming, are strategies that could potentially optimize stem cell transplantation therapy for clinical application. In this review, we discuss the most up-to-date findings related to utilizing preconditioned stem cells for myocardial infarction treatment, focusing mainly on preconditioning with hypoxia, growth factors, drugs, and biological agents. Furthermore, genetic manipulations on stem cells, such as the overexpression of specific proteins, regulation of microRNAs, and cellular reprogramming to improve their efficiency in myocardial infarction treatment, are discussed as well.

show abstract

“…MSCs derived from the aforementioned tissues are usually expanded in vitro to produce a large number of cells, followed by quality control with assays, including surface marker identification, senescent test, immune inhibition assay, and trilineage differentiation. Finally, the cells can be administered for MI treatment in vivo . Animal studies show that MSCs injected intravenously localize mainly in the lungs as spheroids and have very low accumulation in the lesion of the MI .…”

Section: Cell‐based Therapies For MImentioning

confidence: 99%

Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering

Jiang

Shamul

et al. 2020

Advanced Therapeutics

View full text Add to dashboard Cite

Myocardial infarction (MI) is a life‐threatening disease resulting from the irreversible death of cardiomyocytes (CMs). Stem cell‐based therapies have been studied for MI treatment over the last two decades with promising outcomes. Here, the past work in this field is critically reviewed to elucidate the advantages and disadvantages of treating MI using pluripotent stem cells (PSCs) including both embryonic stem cells (ESCs) and induced pluripotent stem cells (iPSCs), adult stem cells, and cardiac progenitor cells. Overall, PSCs (particularly iPSCs) have more advantages than the other cells for cardiac regeneration. However, the use of iPSCs is also facing critical challenges, which may be resolved by using biomaterials to engineer stem cells for reduced immunogenicity, improved immobilization/survival in the heart, and increased integration with the host cardiac tissue to eliminate arrhythmia. Biomaterials have also been applied in the derivation of CMs in vitro to increase the efficiency and maturation of cardiac differentiation. Collectively, a lot has been learned from the past failures of simply injecting intact stem cells or their derivatives in vivo for treating MI, and bioengineering stem cells with biomaterials may be a valuable strategy for advancing stem cell therapy towards its widespread application for MI treatment in the clinic.

show abstract

Functionally Improved Mesenchymal Stem Cells to Better Treat Myocardial Infarction

Cited by 51 publications

References 149 publications

Enhanced In Vivo Delivery of Stem Cells using Microporous Annealed Particle Scaffolds

Enhanced In Vivo Delivery of Stem Cells using Microporous Annealed Particle Scaffolds

Preconditioned and Genetically Modified Stem Cells for Myocardial Infarction Treatment

Stem Cell Therapy of Myocardial Infarction: A Promising Opportunity in Bioengineering

Contact Info

Product

Resources

About